カテゴリー： 世界, 医療/バイオ, QYResearch

ペプチド-薬物複合体の世界市場インサイト・予測（～2028年）

【英語タイトル】Global Peptide-Drug Conjugates Market Insights, Forecast to 2028

QYResearchが出版した調査資料（QY22JLX09270）・商品コード：QY22JLX09270
・発行会社（調査会社）：QYResearch
・発行日：2022年7月（※2025年版があります。お問い合わせください。）
・ページ数：89
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,117,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,489,600見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

COVID-19のパンデミックにより、ペプチド-薬物複合体のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にペプチド-薬物複合体の世界市場のxxx％を占める「細胞透過性ペプチド（CPP）」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「癌腫」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
ペプチド-薬物複合体の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのペプチド-薬物複合体市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

ペプチド-薬物複合体のグローバル主要企業には、AstraZeneca、Bicycle Therapeutics、Cybrexa Therapeutics、Esperance Pharmaceuticals、Oncopeptides、Pepgen Corporation、Soricimed Biopharma、Theratechnologiesなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

ペプチド-薬物複合体市場は、種類と用途によって区分されます。世界のペプチド-薬物複合体市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
細胞透過性ペプチド（CPP）、細胞標的ペプチド（CTP）

【用途別セグメント】
癌腫、肉腫、黒色腫、リンパ腫、白血病

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- ペプチド-薬物複合体製品概要
- 種類別市場（細胞透過性ペプチド（CPP）、細胞標的ペプチド（CTP））
- 用途別市場（癌腫、肉腫、黒色腫、リンパ腫、白血病）
- 調査の目的
・エグゼクティブサマリー
- 世界のペプチド-薬物複合体販売量予測2017-2028
- 世界のペプチド-薬物複合体売上予測2017-2028
- ペプチド-薬物複合体の地域別販売量
- ペプチド-薬物複合体の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別ペプチド-薬物複合体販売量
- 主要メーカー別ペプチド-薬物複合体売上
- 主要メーカー別ペプチド-薬物複合体価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（細胞透過性ペプチド（CPP）、細胞標的ペプチド（CTP））
- ペプチド-薬物複合体の種類別販売量
- ペプチド-薬物複合体の種類別売上
- ペプチド-薬物複合体の種類別価格
・用途別市場規模（癌腫、肉腫、黒色腫、リンパ腫、白血病）
- ペプチド-薬物複合体の用途別販売量
- ペプチド-薬物複合体の用途別売上
- ペプチド-薬物複合体の用途別価格
・北米市場
- 北米のペプチド-薬物複合体市場規模（種類別、用途別）
- 主要国別のペプチド-薬物複合体市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパのペプチド-薬物複合体市場規模（種類別、用途別）
- 主要国別のペプチド-薬物複合体市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋のペプチド-薬物複合体市場規模（種類別、用途別）
- 主要国別のペプチド-薬物複合体市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米のペプチド-薬物複合体市場規模（種類別、用途別）
- 主要国別のペプチド-薬物複合体市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカのペプチド-薬物複合体市場規模（種類別、用途別）
- 主要国別のペプチド-薬物複合体市場規模（トルコ、サウジアラビア）
・企業情報
AstraZeneca、Bicycle Therapeutics、Cybrexa Therapeutics、Esperance Pharmaceuticals、Oncopeptides、Pepgen Corporation、Soricimed Biopharma、Theratechnologies
・産業チェーン及び販売チャネル分析
- ペプチド-薬物複合体の産業チェーン分析
- ペプチド-薬物複合体の原材料
- ペプチド-薬物複合体の生産プロセス
- ペプチド-薬物複合体の販売及びマーケティング
- ペプチド-薬物複合体の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- ペプチド-薬物複合体の産業動向
- ペプチド-薬物複合体のマーケットドライバー
- ペプチド-薬物複合体の課題
- ペプチド-薬物複合体の阻害要因
・主な調査結果

Market Analysis and Insights: Global Peptide-Drug Conjugates Market
The global Peptide-Drug Conjugates market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Cell-penetrating Peptides (CPPs) accounting for % of the Peptide-Drug Conjugates global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Carcinoma segment is altered to an % CAGR throughout this forecast period.
China Peptide-Drug Conjugates market size is valued at US$ million in 2021, while the North America and Europe Peptide-Drug Conjugates are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Peptide-Drug Conjugates landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Peptide-Drug Conjugates market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Peptide-Drug Conjugates market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Peptide-Drug Conjugates market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Peptide-Drug Conjugates market.
Global Peptide-Drug Conjugates Scope and Market Size
Peptide-Drug Conjugates market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Peptide-Drug Conjugates market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Cell-penetrating Peptides (CPPs)
Cell-targeting Peptides (CTPs)
Segment by Application
Carcinoma
Sarcoma
Melanoma
Lymphoma
Leukemia
By Company
AstraZeneca
Bicycle Therapeutics
Cybrexa Therapeutics
Esperance Pharmaceuticals
Oncopeptides
Pepgen Corporation
Soricimed Biopharma
Theratechnologies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide-Drug Conjugates Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Cell-penetrating Peptides (CPPs)
1.2.3 Cell-targeting Peptides (CTPs)
1.3 Market by Application
1.3.1 Global Peptide-Drug Conjugates Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Carcinoma
1.3.3 Sarcoma
1.3.4 Melanoma
1.3.5 Lymphoma
1.3.6 Leukemia
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Peptide-Drug Conjugates Market Perspective (2017-2028)
2.2 Peptide-Drug Conjugates Growth Trends by Region
2.2.1 Peptide-Drug Conjugates Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Peptide-Drug Conjugates Historic Market Size by Region (2017-2022)
2.2.3 Peptide-Drug Conjugates Forecasted Market Size by Region (2023-2028)
2.3 Peptide-Drug Conjugates Market Dynamics
2.3.1 Peptide-Drug Conjugates Industry Trends
2.3.2 Peptide-Drug Conjugates Market Drivers
2.3.3 Peptide-Drug Conjugates Market Challenges
2.3.4 Peptide-Drug Conjugates Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide-Drug Conjugates Players by Revenue
3.1.1 Global Top Peptide-Drug Conjugates Players by Revenue (2017-2022)
3.1.2 Global Peptide-Drug Conjugates Revenue Market Share by Players (2017-2022)
3.2 Global Peptide-Drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peptide-Drug Conjugates Revenue
3.4 Global Peptide-Drug Conjugates Market Concentration Ratio
3.4.1 Global Peptide-Drug Conjugates Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide-Drug Conjugates Revenue in 2021
3.5 Peptide-Drug Conjugates Key Players Head office and Area Served
3.6 Key Players Peptide-Drug Conjugates Product Solution and Service
3.7 Date of Enter into Peptide-Drug Conjugates Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide-Drug Conjugates Breakdown Data by Type
4.1 Global Peptide-Drug Conjugates Historic Market Size by Type (2017-2022)
4.2 Global Peptide-Drug Conjugates Forecasted Market Size by Type (2023-2028)
5 Peptide-Drug Conjugates Breakdown Data by Application
5.1 Global Peptide-Drug Conjugates Historic Market Size by Application (2017-2022)
5.2 Global Peptide-Drug Conjugates Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Peptide-Drug Conjugates Market Size (2017-2028)
6.2 North America Peptide-Drug Conjugates Market Size by Type
6.2.1 North America Peptide-Drug Conjugates Market Size by Type (2017-2022)
6.2.2 North America Peptide-Drug Conjugates Market Size by Type (2023-2028)
6.2.3 North America Peptide-Drug Conjugates Market Share by Type (2017-2028)
6.3 North America Peptide-Drug Conjugates Market Size by Application
6.3.1 North America Peptide-Drug Conjugates Market Size by Application (2017-2022)
6.3.2 North America Peptide-Drug Conjugates Market Size by Application (2023-2028)
6.3.3 North America Peptide-Drug Conjugates Market Share by Application (2017-2028)
6.4 North America Peptide-Drug Conjugates Market Size by Country
6.4.1 North America Peptide-Drug Conjugates Market Size by Country (2017-2022)
6.4.2 North America Peptide-Drug Conjugates Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Peptide-Drug Conjugates Market Size (2017-2028)
7.2 Europe Peptide-Drug Conjugates Market Size by Type
7.2.1 Europe Peptide-Drug Conjugates Market Size by Type (2017-2022)
7.2.2 Europe Peptide-Drug Conjugates Market Size by Type (2023-2028)
7.2.3 Europe Peptide-Drug Conjugates Market Share by Type (2017-2028)
7.3 Europe Peptide-Drug Conjugates Market Size by Application
7.3.1 Europe Peptide-Drug Conjugates Market Size by Application (2017-2022)
7.3.2 Europe Peptide-Drug Conjugates Market Size by Application (2023-2028)
7.3.3 Europe Peptide-Drug Conjugates Market Share by Application (2017-2028)
7.4 Europe Peptide-Drug Conjugates Market Size by Country
7.4.1 Europe Peptide-Drug Conjugates Market Size by Country (2017-2022)
7.4.2 Europe Peptide-Drug Conjugates Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide-Drug Conjugates Market Size (2017-2028)
8.2 Asia-Pacific Peptide-Drug Conjugates Market Size by Type
8.2.1 Asia-Pacific Peptide-Drug Conjugates Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Peptide-Drug Conjugates Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Peptide-Drug Conjugates Market Share by Type (2017-2028)
8.3 Asia-Pacific Peptide-Drug Conjugates Market Size by Application
8.3.1 Asia-Pacific Peptide-Drug Conjugates Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Peptide-Drug Conjugates Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Peptide-Drug Conjugates Market Share by Application (2017-2028)
8.4 Asia-Pacific Peptide-Drug Conjugates Market Size by Region
8.4.1 Asia-Pacific Peptide-Drug Conjugates Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Peptide-Drug Conjugates Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Peptide-Drug Conjugates Market Size (2017-2028)
9.2 Latin America Peptide-Drug Conjugates Market Size by Type
9.2.1 Latin America Peptide-Drug Conjugates Market Size by Type (2017-2022)
9.2.2 Latin America Peptide-Drug Conjugates Market Size by Type (2023-2028)
9.2.3 Latin America Peptide-Drug Conjugates Market Share by Type (2017-2028)
9.3 Latin America Peptide-Drug Conjugates Market Size by Application
9.3.1 Latin America Peptide-Drug Conjugates Market Size by Application (2017-2022)
9.3.2 Latin America Peptide-Drug Conjugates Market Size by Application (2023-2028)
9.3.3 Latin America Peptide-Drug Conjugates Market Share by Application (2017-2028)
9.4 Latin America Peptide-Drug Conjugates Market Size by Country
9.4.1 Latin America Peptide-Drug Conjugates Market Size by Country (2017-2022)
9.4.2 Latin America Peptide-Drug Conjugates Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide-Drug Conjugates Market Size (2017-2028)
10.2 Middle East & Africa Peptide-Drug Conjugates Market Size by Type
10.2.1 Middle East & Africa Peptide-Drug Conjugates Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Peptide-Drug Conjugates Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Peptide-Drug Conjugates Market Share by Type (2017-2028)
10.3 Middle East & Africa Peptide-Drug Conjugates Market Size by Application
10.3.1 Middle East & Africa Peptide-Drug Conjugates Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Peptide-Drug Conjugates Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Peptide-Drug Conjugates Market Share by Application (2017-2028)
10.4 Middle East & Africa Peptide-Drug Conjugates Market Size by Country
10.4.1 Middle East & Africa Peptide-Drug Conjugates Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Peptide-Drug Conjugates Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Peptide-Drug Conjugates Introduction
11.1.4 AstraZeneca Revenue in Peptide-Drug Conjugates Business (2017-2022)
11.1.5 AstraZeneca Recent Developments
11.2 Bicycle Therapeutics
11.2.1 Bicycle Therapeutics Company Details
11.2.2 Bicycle Therapeutics Business Overview
11.2.3 Bicycle Therapeutics Peptide-Drug Conjugates Introduction
11.2.4 Bicycle Therapeutics Revenue in Peptide-Drug Conjugates Business (2017-2022)
11.2.5 Bicycle Therapeutics Recent Developments
11.3 Cybrexa Therapeutics
11.3.1 Cybrexa Therapeutics Company Details
11.3.2 Cybrexa Therapeutics Business Overview
11.3.3 Cybrexa Therapeutics Peptide-Drug Conjugates Introduction
11.3.4 Cybrexa Therapeutics Revenue in Peptide-Drug Conjugates Business (2017-2022)
11.3.5 Cybrexa Therapeutics Recent Developments
11.4 Esperance Pharmaceuticals
11.4.1 Esperance Pharmaceuticals Company Details
11.4.2 Esperance Pharmaceuticals Business Overview
11.4.3 Esperance Pharmaceuticals Peptide-Drug Conjugates Introduction
11.4.4 Esperance Pharmaceuticals Revenue in Peptide-Drug Conjugates Business (2017-2022)
11.4.5 Esperance Pharmaceuticals Recent Developments
11.5 Oncopeptides
11.5.1 Oncopeptides Company Details
11.5.2 Oncopeptides Business Overview
11.5.3 Oncopeptides Peptide-Drug Conjugates Introduction
11.5.4 Oncopeptides Revenue in Peptide-Drug Conjugates Business (2017-2022)
11.5.5 Oncopeptides Recent Developments
11.6 Pepgen Corporation
11.6.1 Pepgen Corporation Company Details
11.6.2 Pepgen Corporation Business Overview
11.6.3 Pepgen Corporation Peptide-Drug Conjugates Introduction
11.6.4 Pepgen Corporation Revenue in Peptide-Drug Conjugates Business (2017-2022)
11.6.5 Pepgen Corporation Recent Developments
11.7 Soricimed Biopharma
11.7.1 Soricimed Biopharma Company Details
11.7.2 Soricimed Biopharma Business Overview
11.7.3 Soricimed Biopharma Peptide-Drug Conjugates Introduction
11.7.4 Soricimed Biopharma Revenue in Peptide-Drug Conjugates Business (2017-2022)
11.7.5 Soricimed Biopharma Recent Developments
11.8 Theratechnologies
11.8.1 Theratechnologies Company Details
11.8.2 Theratechnologies Business Overview
11.8.3 Theratechnologies Peptide-Drug Conjugates Introduction
11.8.4 Theratechnologies Revenue in Peptide-Drug Conjugates Business (2017-2022)
11.8.5 Theratechnologies Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Peptide-Drug Conjugates Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Cell-penetrating Peptides (CPPs)
Table 3. Key Players of Cell-targeting Peptides (CTPs)
Table 4. Global Peptide-Drug Conjugates Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global Peptide-Drug Conjugates Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Peptide-Drug Conjugates Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Peptide-Drug Conjugates Market Share by Region (2017-2022)
Table 8. Global Peptide-Drug Conjugates Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Peptide-Drug Conjugates Market Share by Region (2023-2028)
Table 10. Peptide-Drug Conjugates Market Trends
Table 11. Peptide-Drug Conjugates Market Drivers
Table 12. Peptide-Drug Conjugates Market Challenges
Table 13. Peptide-Drug Conjugates Market Restraints
Table 14. Global Peptide-Drug Conjugates Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Peptide-Drug Conjugates Revenue Share by Players (2017-2022)
Table 16. Global Top Peptide-Drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-Drug Conjugates as of 2021)
Table 17. Ranking of Global Top Peptide-Drug Conjugates Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Peptide-Drug Conjugates Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Peptide-Drug Conjugates Product Solution and Service
Table 21. Date of Enter into Peptide-Drug Conjugates Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Peptide-Drug Conjugates Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Peptide-Drug Conjugates Revenue Market Share by Type (2017-2022)
Table 25. Global Peptide-Drug Conjugates Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Peptide-Drug Conjugates Revenue Market Share by Type (2023-2028)
Table 27. Global Peptide-Drug Conjugates Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Peptide-Drug Conjugates Revenue Share by Application (2017-2022)
Table 29. Global Peptide-Drug Conjugates Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Peptide-Drug Conjugates Revenue Share by Application (2023-2028)
Table 31. North America Peptide-Drug Conjugates Market Size by Type (2017-2022) & (US$ Million)
Table 32. North America Peptide-Drug Conjugates Market Size by Type (2023-2028) & (US$ Million)
Table 33. North America Peptide-Drug Conjugates Market Size by Application (2017-2022) & (US$ Million)
Table 34. North America Peptide-Drug Conjugates Market Size by Application (2023-2028) & (US$ Million)
Table 35. North America Peptide-Drug Conjugates Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Peptide-Drug Conjugates Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Peptide-Drug Conjugates Market Size by Type (2017-2022) & (US$ Million)
Table 38. Europe Peptide-Drug Conjugates Market Size by Type (2023-2028) & (US$ Million)
Table 39. Europe Peptide-Drug Conjugates Market Size by Application (2017-2022) & (US$ Million)
Table 40. Europe Peptide-Drug Conjugates Market Size by Application (2023-2028) & (US$ Million)
Table 41. Europe Peptide-Drug Conjugates Market Size by Country (2017-2022) & (US$ Million)
Table 42. Europe Peptide-Drug Conjugates Market Size by Country (2023-2028) & (US$ Million)
Table 43. Asia Pacific Peptide-Drug Conjugates Market Size by Type (2017-2022) & (US$ Million)
Table 44. Asia Pacific Peptide-Drug Conjugates Market Size by Type (2023-2028) & (US$ Million)
Table 45. Asia Pacific Peptide-Drug Conjugates Market Size by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific Peptide-Drug Conjugates Market Size by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific Peptide-Drug Conjugates Market Size by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific Peptide-Drug Conjugates Market Size by Region (2023-2028) & (US$ Million)
Table 49. Latin America Peptide-Drug Conjugates Market Size by Type (2017-2022) & (US$ Million)
Table 50. Latin America Peptide-Drug Conjugates Market Size by Type (2023-2028) & (US$ Million)
Table 51. Latin America Peptide-Drug Conjugates Market Size by Application (2017-2022) & (US$ Million)
Table 52. Latin America Peptide-Drug Conjugates Market Size by Application (2023-2028) & (US$ Million)
Table 53. Latin America Peptide-Drug Conjugates Market Size by Country (2017-2022) & (US$ Million)
Table 54. Latin America Peptide-Drug Conjugates Market Size by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Peptide-Drug Conjugates Market Size by Type (2017-2022) & (US$ Million)
Table 56. Middle East and Africa Peptide-Drug Conjugates Market Size by Type (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Peptide-Drug Conjugates Market Size by Application (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Peptide-Drug Conjugates Market Size by Application (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Peptide-Drug Conjugates Market Size by Country (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Peptide-Drug Conjugates Market Size by Country (2023-2028) & (US$ Million)
Table 61. AstraZeneca Company Details
Table 62. AstraZeneca Business Overview
Table 63. AstraZeneca Peptide-Drug Conjugates Product
Table 64. AstraZeneca Revenue in Peptide-Drug Conjugates Business (2017-2022) & (US$ Million)
Table 65. AstraZeneca Recent Developments
Table 66. Bicycle Therapeutics Company Details
Table 67. Bicycle Therapeutics Business Overview
Table 68. Bicycle Therapeutics Peptide-Drug Conjugates Product
Table 69. Bicycle Therapeutics Revenue in Peptide-Drug Conjugates Business (2017-2022) & (US$ Million)
Table 70. Bicycle Therapeutics Recent Developments
Table 71. Cybrexa Therapeutics Company Details
Table 72. Cybrexa Therapeutics Business Overview
Table 73. Cybrexa Therapeutics Peptide-Drug Conjugates Product
Table 74. Cybrexa Therapeutics Revenue in Peptide-Drug Conjugates Business (2017-2022) & (US$ Million)
Table 75. Cybrexa Therapeutics Recent Developments
Table 76. Esperance Pharmaceuticals Company Details
Table 77. Esperance Pharmaceuticals Business Overview
Table 78. Esperance Pharmaceuticals Peptide-Drug Conjugates Product
Table 79. Esperance Pharmaceuticals Revenue in Peptide-Drug Conjugates Business (2017-2022) & (US$ Million)
Table 80. Esperance Pharmaceuticals Recent Developments
Table 81. Oncopeptides Company Details
Table 82. Oncopeptides Business Overview
Table 83. Oncopeptides Peptide-Drug Conjugates Product
Table 84. Oncopeptides Revenue in Peptide-Drug Conjugates Business (2017-2022) & (US$ Million)
Table 85. Oncopeptides Recent Developments
Table 86. Pepgen Corporation Company Details
Table 87. Pepgen Corporation Business Overview
Table 88. Pepgen Corporation Peptide-Drug Conjugates Product
Table 89. Pepgen Corporation Revenue in Peptide-Drug Conjugates Business (2017-2022) & (US$ Million)
Table 90. Pepgen Corporation Recent Developments
Table 91. Soricimed Biopharma Company Details
Table 92. Soricimed Biopharma Business Overview
Table 93. Soricimed Biopharma Peptide-Drug Conjugates Product
Table 94. Soricimed Biopharma Revenue in Peptide-Drug Conjugates Business (2017-2022) & (US$ Million)
Table 95. Soricimed Biopharma Recent Developments
Table 96. Theratechnologies Company Details
Table 97. Theratechnologies Business Overview
Table 98. Theratechnologies Peptide-Drug Conjugates Product
Table 99. Theratechnologies Revenue in Peptide-Drug Conjugates Business (2017-2022) & (US$ Million)
Table 100. Theratechnologies Recent Developments
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide-Drug Conjugates Market Share by Type: 2021 VS 2028
Figure 2. Cell-penetrating Peptides (CPPs) Features
Figure 3. Cell-targeting Peptides (CTPs) Features
Figure 4. Global Peptide-Drug Conjugates Market Share by Application: 2021 VS 2028
Figure 5. Carcinoma Case Studies
Figure 6. Sarcoma Case Studies
Figure 7. Melanoma Case Studies
Figure 8. Lymphoma Case Studies
Figure 9. Leukemia Case Studies
Figure 10. Peptide-Drug Conjugates Report Years Considered
Figure 11. Global Peptide-Drug Conjugates Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 12. Global Peptide-Drug Conjugates Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Peptide-Drug Conjugates Market Share by Region: 2021 VS 2028
Figure 14. Global Peptide-Drug Conjugates Market Share by Players in 2021
Figure 15. Global Top Peptide-Drug Conjugates Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-Drug Conjugates as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Peptide-Drug Conjugates Revenue in 2021
Figure 17. North America Peptide-Drug Conjugates Market Size YoY (2017-2028) & (US$ Million)
Figure 18. North America Peptide-Drug Conjugates Market Size Market Share by Type (2017-2028)
Figure 19. North America Peptide-Drug Conjugates Market Size Market Share by Application (2017-2028)
Figure 20. North America Peptide-Drug Conjugates Market Size Share by Country (2017-2028)
Figure 21. United States Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Peptide-Drug Conjugates Market Size YoY (2017-2028) & (US$ Million)
Figure 24. Europe Peptide-Drug Conjugates Market Size Market Share by Type (2017-2028)
Figure 25. Europe Peptide-Drug Conjugates Market Size Market Share by Application (2017-2028)
Figure 26. Europe Peptide-Drug Conjugates Market Size Share by Country (2017-2028)
Figure 27. Germany Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. France Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. U.K. Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Italy Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Russia Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Nordic Countries Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Peptide-Drug Conjugates Market Size YoY (2017-2028) & (US$ Million)
Figure 34. Asia Pacific Peptide-Drug Conjugates Market Size Market Share by Type (2017-2028)
Figure 35. Asia Pacific Peptide-Drug Conjugates Market Size Market Share by Application (2017-2028)
Figure 36. Asia Pacific Peptide-Drug Conjugates Market Size Share by Region (2017-2028)
Figure 37. China Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Japan Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. South Korea Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Southeast Asia Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. India Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Australia Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 43. Latin America Peptide-Drug Conjugates Market Size YoY (2017-2028) & (US$ Million)
Figure 44. Latin America Peptide-Drug Conjugates Market Size Market Share by Type (2017-2028)
Figure 45. Latin America Peptide-Drug Conjugates Market Size Market Share by Application (2017-2028)
Figure 46. Latin America Peptide-Drug Conjugates Market Size Share by Country (2017-2028)
Figure 47. Mexico Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Brazil Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Middle East & Africa Peptide-Drug Conjugates Market Size YoY (2017-2028) & (US$ Million)
Figure 50. Middle East and Africa Peptide-Drug Conjugates Market Size Market Share by Type (2017-2028)
Figure 51. Middle East and Africa Peptide-Drug Conjugates Market Size Market Share by Application (2017-2028)
Figure 52. Middle East and Africa Peptide-Drug Conjugates Market Size Share by Country (2017-2028)
Figure 53. Turkey Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. UAE Peptide-Drug Conjugates Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. AstraZeneca Revenue Growth Rate in Peptide-Drug Conjugates Business (2017-2022)
Figure 57. Bicycle Therapeutics Revenue Growth Rate in Peptide-Drug Conjugates Business (2017-2022)
Figure 58. Cybrexa Therapeutics Revenue Growth Rate in Peptide-Drug Conjugates Business (2017-2022)
Figure 59. Esperance Pharmaceuticals Revenue Growth Rate in Peptide-Drug Conjugates Business (2017-2022)
Figure 60. Oncopeptides Revenue Growth Rate in Peptide-Drug Conjugates Business (2017-2022)
Figure 61. Pepgen Corporation Revenue Growth Rate in Peptide-Drug Conjugates Business (2017-2022)
Figure 62. Soricimed Biopharma Revenue Growth Rate in Peptide-Drug Conjugates Business (2017-2022)
Figure 63. Theratechnologies Revenue Growth Rate in Peptide-Drug Conjugates Business (2017-2022)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed


★調査レポート[ペプチド-薬物複合体の世界市場インサイト・予測（～2028年）] (コード：QY22JLX09270)販売に関する免責事項を必ずご確認ください。
★調査レポート[ペプチド-薬物複合体の世界市場インサイト・予測（～2028年）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 経口ペプチド薬の世界市場インサイト・予測（～2028年）
  • 注射ペプチド薬の世界市場インサイト・予測（～2028年）
  • アジュバントペプチドの世界市場インサイト・予測（～2028年）
  • 統合失調症関連ペプチドの世界市場インサイト・予測（～2028年）
  • ガストリン放出ペプチドの世界市場インサイト・予測（～2028年）

    • ◆H&Iグローバルリサーチのお客様（例）◆